ArriVent BioPharma, Inc. Common Stock (AVBP)vsModerna Inc (MRNA)
AVBP
ArriVent BioPharma, Inc. Common Stock
$29.00
+1.05%
HEALTHCARE · Cap: $1.43B
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
AVBP leads profitability with a 0.0% profit margin vs -141.4%. AVBP earns a higher WallStSmart Score of 26/100 (F).
AVBP
Avoid26
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVBP.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AVBP
The strongest argument for AVBP centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : AVBP
The primary concerns for AVBP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AVBP profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
AVBP carries more volatility with a beta of 1.36 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
AVBP generates stronger free cash flow (-40M), providing more financial flexibility.
Bottom Line
AVBP scores higher overall (26/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ArriVent BioPharma, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
ArriVent BioPharma, Inc. (AVBP) is an innovative biopharmaceutical company committed to advancing groundbreaking therapies for critical unmet needs in oncology and autoimmune diseases. Leveraging proprietary technologies and a robust scientific foundation, ArriVent is focused on delivering improved patient outcomes through its promising pipeline. With strategic positioning in high-growth sectors of the biopharma industry, the company represents an attractive investment opportunity for institutional investors seeking to capitalize on transformative healthcare advancements with the potential for significant market impact.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?